Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer.

Yen-Han Tseng,Heng-Sheng Chao,Yuh-Min Chen,Jen-Fu Shih

doi:10.7717/peerj.7767

Yen-Han Tseng, Heng-Sheng Chao + Show 2 more

Open Access

https://doi.org/10.7717/peerj.7767

Copy DOI

Abstract

BackgroundLater line chemotherapy (≥2nd lines) such as Docetaxel or immunotherapy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted.MethodsWe retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected.ResultsTwenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25%). The disease control rate was 60.7% (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type.ConclusionsTTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.

Highlights

Median survival time of patients with metastatic non-small cell lung cancer (NSCLC) has increased in recent two decades after usage of molecular targeted therapy and immunotherapy (Hamid et al, 2019; Planchard et al, 2019)
To evaluate the effectiveness of the efficacy of paclitaxel plus TS1 (TTS1), we retrospectively reviewed the cohort from different perspectives
There were 28 stage IV NSCLC patients enrolled in this study

Summary

Introduction

Median survival time of patients with metastatic non-small cell lung cancer (NSCLC) has increased in recent two decades after usage of molecular targeted therapy and immunotherapy (Hamid et al, 2019; Planchard et al, 2019). Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer. As for regimens of chemotherapy, previous studies showed combination therapy is better than single agent treatment for NSCLC patients (Lilenbaum et al, 2009; Morth & Valachis, 2014). We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs 1.8 months) and OS (15.5 months vs 7.2 months) compared with those of EGFR wild type. TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found

Methods

Results

Conclusion